Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper
Sonu Bhaskar, Akansha Sinha, Maciej Banach, Shikha Mittoo, Robert Weissert, Joseph S Kass, Santhosh Rajagopal, Anupama R Pai, Shelby Kutty, Sonu Bhaskar, Akansha Sinha, Maciej Banach, Shikha Mittoo, Robert Weissert, Joseph S Kass, Santhosh Rajagopal, Anupama R Pai, Shelby Kutty
Abstract
Cytokine storm is an acute hyperinflammatory response that may be responsible for critical illness in many conditions including viral infections, cancer, sepsis, and multi-organ failure. The phenomenon has been implicated in critically ill patients infected with SARS-CoV-2, the novel coronavirus implicated in COVID-19. Critically ill COVID-19 patients experiencing cytokine storm are believed to have a worse prognosis and increased fatality rate. In SARS-CoV-2 infected patients, cytokine storm appears important to the pathogenesis of several severe manifestations of COVID-19: acute respiratory distress syndrome, thromboembolic diseases such as acute ischemic strokes caused by large vessel occlusion and myocardial infarction, encephalitis, acute kidney injury, and vasculitis (Kawasaki-like syndrome in children and renal vasculitis in adult). Understanding the pathogenesis of cytokine storm will help unravel not only risk factors for the condition but also therapeutic strategies to modulate the immune response and deliver improved outcomes in COVID-19 patients at high risk for severe disease. In this article, we present an overview of the cytokine storm and its implications in COVID-19 settings and identify potential pathways or biomarkers that could be targeted for therapy. Leveraging expert opinion, emerging evidence, and a case-based approach, this position paper provides critical insights on cytokine storm from both a prognostic and therapeutic standpoint.
Keywords: COVID-19; autoimmunity; critical care; cytokine storm; guidelines; immunological mechanisms; immunotherapies; neuroimmunology.
Copyright © 2020 Bhaskar, Sinha, Banach, Mittoo, Weissert, Kass, Rajagopal, Pai and Kutty.
Figures
References
- Mehta P, McAuley D, Brown M, Sanchez E, Tattersall R, Manson J. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. (2020) 395:1033–4. 10.1016/S0140-6736(20)30628-0
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497–506. 10.1016/S0140-6736(20)30183-5
- Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. (2020) 46:846–8. 10.1007/s00134-020-05991-x
- Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. . Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. (2020) e201017. 10.1001/jamacardio.2020.1017.
- Vaninov N. In the eye of the COVID-19 cytokine storm. Nat Rev Immunol. (2020) 20:277. 10.1038/s41577-020-0305-6
- Weaver LK, Behrens EM. Weathering the storm: improving therapeutic interventions for cytokine storm syndromes by targeting disease pathogenesis. Curr Treatm Opt Rheumatol. (2017) 3:33–48. 10.1007/s40674-017-0059-x
- Katsiki N, Banach M, Mikhailidis DP. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic. Arch Med Sci. (2020) 16:485–9. 10.5114/aoms.2020.94503
- Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. . Endothelial cell infection and endotheliitis in COVID-19. Lancet. (2020) 395:1417–8. 10.1016/s0140-6736(20)30937-5
- Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. . The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. (2020) 7:11. 10.1186/s40779-020-00240-0
- Dolhnikoff M, Duarte-Neto AN, de Almeida Monteiro RA, da Silva LFF, de Oliveira EP, Saldiva PHN, et al. . Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost. (2020) 18:1517–9. 10.1111/jth.14844
- Liu Q, Zhou Y-H, Yang Z-Q. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol. (2016) 13:3–10. 10.1038/cmi.2015.74
- Rabb H. Kidney diseases in the time of COVID-19: major challenges to patient care. J Clin Invest. (2020) 130:2749–51. 10.1172/jci138871
- Perico L, Benigni A, Remuzzi G. Should COVID-19 concern nephrologists? why and to what extent? the emerging impasse of angiotensin blockade. Nephron. (2020) 144:213–21. 10.1159/000507305
- Bhaskar S, Rastogi A, Chattu VK, Adisesh A, Thomas P, Alvarado N, et al. . Key strategies for clinical management and improvement of healthcare services for cardiovascular disease and diabetes patients in the coronavirus (COVID-19) settings: recommendations from the REPROGRAM Consortium. Front Cardiovasc Med. (2020) 7:112. 10.3389/fcvm.2020.00112
- Banach M, Penson PE, Fras Z, Vrablik M, Pella D, Reiner Ž, et al. . Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic. Pharmacol Res. (2020) 158:104891. 10.1016/j.phrs.2020.104891
- Reiner Ž, Hatamipour M, Banach M, Pirro M, Al-Rasadi K, Jamialahmadi T, et al. . Statins and the COVID-19 main protease: in silico evidence on direct interaction. Arch Med Sci. (2020) 16:490–6. 10.5114/aoms.2020.94655
- Doyen D, Moceri P, Ducreux D, Dellamonica J. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes. Lancet. (2020) 395:1516. 10.1016/s0140-6736(20)30912-0
- Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol.(2020). 10.1001/jamacardio.2020.1286
- Banach M, Serban C, Sahebkar A, Mikhailidis DP, Ursoniu S, Ray KK, et al. . Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. BMC Med. (2015) 13:229. 10.1186/s12916-015-0459-4
- Robinson CP, Busl KM. Neurologic manifestations of severe respiratory viral contagions. Crit Care Explor. (2020) 2:e0107–e. 10.1097/CCE.0000000000000107
- Nath A. Neurologic complications of coronavirus infections. Neurology. (2020) 94:809–10. 10.1212/wnl.0000000000009455
- Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al. . A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis. (2020) 94:55–8. 10.1016/j.ijid.2020.03.062
- Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. (2020) 92:552–5. 10.1002/jmv.25728
- Bhaskar S, Sharma D, Walker AH, McDonald M, Huasen B, Haridas A, et al. . Acute neurological care in the COVID-19 era: the pandemic health system REsilience PROGRAM (REPROGRAM) consortium pathway. Front Neurol. (2020) 11:579. 10.3389/fneur.2020.00579
- Bhaskar S, Bradley S, Israeli-Korn S, Menon B, Chattu VK, Thomas P, et al. Chronic neurology in COVID-19 era: clinical considerations and recommendations from the REPROGRAM Consortium. Front Neurol. (2020) 11:664 10.3389/fneur.2020.00664
- Bryce C, Grimes Z, Pujadas E, Ahuja S, Beasley MB, Albrecht R, et al. Pathophysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response. The Mount Sinai COVID-19 autopsy experience. medRxiv. (2020) 2020.05.18.20099960 10.1101/2020.05.18.20099960
- Solomon IH, Normandin E, Bhattacharyya S, Mukerji SS, Keller K, Ali AS, et al. . Neuropathological features of Covid-19. N Engl J Med. (2020). 10.1056/NEJMc2019373
- Paniz-Mondolfi A, Bryce C, Grimes Z, Gordon RE, Reidy J, Lednicky J, et al. . Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol. (2020) 92:699–702. 10.1002/jmv.25915
- Gomez-Pinedo U, Matias-Guiu J, Sanclemente-Alaman I, Moreno-Jimenez L, Montero-Escribano P, Matias-Guiu JA. Is the brain a reservoir organ for SARS-CoV2? J Med Virol. (2020). 10.1002/jmv.26046
- von Weyhern CH, Kaufmann I, Neff F, Kremer M. Early evidence of pronounced brain involvement in fatal COVID-19 outcomes. Lancet. (2020) 395:e109–e. 10.1016/S0140-6736(20)31282-4.
- Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. . Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect. (2020) 80:639–45. 10.1016/j.jinf.2020.03.019
- Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population. Immunology. (2007) 120:435–46. 10.1111/j.1365-2567.2007.02555.x
- Del Giudice G, Goronzy JJ, Grubeck-Loebenstein B, Lambert P-H, Mrkvan T, Stoddard JJ, et al. . Fighting against a protean enemy: immunosenescence, vaccines, and healthy aging. npj Aging Mech Dis. (2017) 4:1. 10.1038/s41514-017-0020-0
- Li M, Yao D, Zeng X, Kasakovski D, Zhang Y, Chen S, et al. . Age related human T cell subset evolution and senescence. Immun Ageing. (2019) 16:24. 10.1186/s12979-019-0165-8
- Weng N-p, Akbar AN, Goronzy J. CD28 T cells: their role in the age-associated decline of immune function. Trends Immunol. (2009) 30:306–12. 10.1016/j.it.2009.03.013
- Bektas A, Schurman SH, Sen R, Ferrucci L. Human T cell immunosenescence and inflammation in aging. J Leukoc Biol. (2017) 102:977–88. 10.1189/jlb.3RI0716-335R
- Wong P, Pamer EG. CD8 T cell responses to infectious pathogens. Annu Rev Immunol. (2003) 21:29–70. 10.1146/annurev.immunol.21.120601.141114
- Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. . Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 Pneumonia. Aging Dis. (2020) 11:216–28. 10.14336/ad.2020.0228
- Panigrahy D, Gilligan MM, Huang S, Gartung A, Cortés-Puch I, Sime PJ, et al. . Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19? Cancer Metastasis Rev. (2020) 39:337–40. 10.1007/s10555-020-09889-4
- Favalli E, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: faraway, so close! Autoimmun Rev. (2020) 19:102523. 10.1016/j.autrev.2020.102523
- Schulert GS, Cron RQ. The genetics of macrophage activation syndrome. Genes Immun. (2020) 21:169–81. 10.1038/s41435-020-0098-4
- Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. . Reduction and functional exhaustion of t cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. (2020) 11:827. 10.3389/fimmu.2020.00827
- Kennedy RH, Silver R. Neuroimmune signaling: cytokines and the CNS, In: Pfaff DW, Volkow ND, editors. Neuroscience in the 21st Century. New York, NY: Springer New York; (2016). p. 1–41. 10.1007/978-1-4614-6434-1_174-1
- Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther. (2006) 8(Suppl. 2):S3. 10.1186/ar1917
- Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. (2020) 17:259–60. 10.1038/s41569-020-0360-5
- Gu J, Han B, Wang J. COVID-19: gastrointestinal manifestations and potential fecal–oral transmission. Gastroenterology. (2020) 158:1518–9. 10.1053/j.gastro.2020.02.054
- Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. (2020) 109:102433. 10.1016/j.jaut.2020.102433
- Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. . Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. (2020) 77:1–9. 10.1001/jamaneurol.2020.1127
- Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. (2020) 5:428–30. 10.1016/s2468-1253(20)30057-1
- Savarin C, Bergmann CC. Fine tuning the cytokine storm by IFN and IL-10 following neurotropic coronavirus encephalomyelitis. Front Immunol. (2018) 9:3022. 10.3389/fimmu.2018.03022
- Morichi S, Yamanaka G, Ishida Y, Oana S, Kashiwagi Y, Kawashima H. Brain-derived neurotrophic factor and interleukin-6 levels in the serum and cerebrospinal fluid of children with viral infection-induced encephalopathy. Neurochem Res. (2014) 39:2143–9. 10.1007/s11064-014-1409-9
- European Society of Cardiology (ESC) ESC Guidance for the Diagnosis and Management of CV Disease During the COVID-19 Pandemic. Available online at: (accessed April 20, 2020).
- Bai HX, Hsieh B, Xiong Z, Halsey K, Choi JW, Tran TML, et al. . Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT. Radiology. (2020) 200823. 10.1148/radiol.2020200823
- Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. . Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. (2020) 20:425–34. 10.1016/s1473-3099(20)30086-4
- Ostad SP, Haseli S, Iranpour P. CT Manifestation of COVID-19 Pneumonia; role of multiplanar imaging. Acad Radiol. (2020) 27:753–4. 10.1016/j.acra.2020.03.028
- Lee EYP, Ng M-Y, Khong P-L. COVID-19 pneumonia: what has CT taught us? Lancet Infect Dis. (2020) 20:384–5. 10.1016/S1473-3099(20)30134-1
- Zhao W, Zhong Z, Xie X, Yu Q, Liu J. Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) Pneumonia: a multicenter study. Am J Roentgenol. (2020) 214:1072–7. 10.2214/AJR.20.22976
- Rubin GD, Ryerson CJ, Haramati LB, Sverzellati N, Kanne JP, Raoof S, et al. The role of chest imaging in patient management during the COVID-19 pandemic: a multinational consensus statement from the Fleischner Society. Chest. (2020). 10.1016/j.chest.2020.04.003
- Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. . Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19). Radiology. (2020) 295:715–21. 10.1148/radiol.2020200370
- Rodrigues JCL, Hare SS, Edey A, Devaraj A, Jacob J, Johnstone A, et al. . An update on COVID-19 for the radiologist - A British society of Thoracic Imaging statement. Clin Radiol. (2020) 75:323–5. 10.1016/j.crad.2020.03.003
- Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. . COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. (2020) 75:2950–73. 10.1016/j.jacc.2020.04.031
- Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. . Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med. (2020) 382:e60. 10.1056/NEJMc2009787
- Tavazzi G, Civardi L, Caneva L, Mongodi S, Mojoli F. Thrombotic events in SARS-CoV-2 patients: an urgent call for ultrasound screening. Intensive care Med. (2020) 46:1121–3. 10.1007/s00134-020-06040-3
- Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. (2020) 18:1421–4. 10.1111/jth.14830
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. (2020) 395:1054–62. 10.1016/s0140-6736(20)30566-3
- Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. (2020) 191:145–7. 10.1016/j.thromres.2020.04.013
- Fox SE, Akmatbekov A, Harbert JL, Li G, Brown JQ, Vander Heide RS. Pulmonary and cardiac pathology in Covid-19: the first autopsy series from New Orleans. medRxiv. (2020) 2020.04.06.20050575. 10.1101/2020.04.06.20050575
- Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. (2020) 18:1094–9. 10.1111/jth.14817
- Xiong M, Liang X, Wei YD. Changes in blood coagulation in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. Br J Haematol. (2020) 189:1050–2. 10.1111/bjh.16725
- American Society of Haematology COVID-19 and VTE/Anticoagulation: Frequently Asked Questions. Available online at: (accessed April 26, 2020).
- Alhazzani W, Lim W, Jaeschke RZ, Murad MH, Cade J, Cook DJ. Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care Med. (2013) 41:2088–98. 10.1097/CCM.0b013e31828cf104
- Simcock R, Thomas TV, Estes C, Filippi AR, Katz MA, Pereira IJ, et al. . COVID-19: Global radiation oncology's targeted response for pandemic preparedness. Clin Transl Radiat Oncol. (2020) 22:55–68. 10.1016/j.ctro.2020.03.009
- Burki TK. Cancer guidelines during the COVID-19 pandemic. Lancet Oncol. (2020) 21:629–30. 10.1016/S1470-2045(20)30217-5
- Chow R, Hoskin P, Schild SE, Raman S, Im J, Zhang D, et al. . Single vs multiple fraction palliative radiation therapy for bone metastases: cumulative meta-analysis. Radiother Oncol. (2019) 141:56–61. 10.1016/j.radonc.2019.06.037
- Weinkove R, McQuilten ZK, Adler J, Agar MR, Blyth E, Cheng AC, et al. . Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. Med J Aust. (2020) 212:481–9. 10.5694/mja2.50607
- Cho S-Y, Lee H-J, Lee D-G. Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea. Korean J Intern Med. (2018) 33:256–76. 10.3904/kjim.2018.036
- Infectious Diseases Society of America COVID-19: Special Considerations for People Living With HIV. Available online at: (accessed May 4, 2020).
- Goldenberg DL. How Clinicians Can Manage Rheumatic and Immune Diseases During COVID-19. Available online at: (accessed May 8, 2020).
- Botha-Scheepers SA, Sarembock B. Infections in the management of rheumatic diseases: an update. S Afr Med J. (2015) 105:1076. 10.7196/samj.2015.v105i12.10220
- Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, et al. . American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 1. Arthrit Rheumatol. (2020). 10.1002/art.41301
- Schulze-Koops H, Specker C, Iking-Konert C, Holle J, Moosig F, Krueger K. Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/COVID-19 pandemic. Ann Rheum Dis. (2020) 79:840–2. 10.1136/annrheumdis-2020-217628
- MS Australia. COVID-19 Information for People With MS. Available online at: (accessed May 2, 2020).
- Crosby JC, Heimann MA, Burleson SL, Anzalone BC, Swanson JF, Wallace DW, et al. COVID-19: a review of therapeutics under investigation. J Am Coll Emerg Physicians Open. (2020) 1:231–7. 10.1002/emp2.12081
- Feldmann M, Maini RN, Woody JN, Holgate ST, Winter G, Rowland M, et al. . Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. (2020) 395:1407–9. 10.1016/s0140-6736(20)30858-8
- Gerlach H. Agents to reduce cytokine storm. F1000Res. (2016) 5:2909. 10.12688/f1000research.9092.1
- Shoenfeld Y. Corona (COVID-19) time musings: our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning. Autoimmun Rev. (2020) 19:102538. 10.1016/j.autrev.2020.102538
- Sindone A, Erlich J, Perkovic V, Suranyi M, Newman H, Lee C, et al. . ACEIs for cardiovascular risk reduction–have we taken our eye off the ball? Aust Fam Physician. (2013) 42:634–8.
- Zhang P, Zhu L, Cai J, Lei F, Qin J-J, Xie J, et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. (2020) 126:1671–81. 10.1161/CIRCRESAHA.120.317134
- Ciavarella C, Motta I, Valente S, Pasquinelli G. Pharmacological (or synthetic) and nutritional agonists of PPAR-γ as candidates for cytokine storm modulation in COVID-19 disease. Molecules. (2020) 25. 10.3390/molecules25092076
- Ghaffari S, Roshanravan N, Tutunchi H, Ostadrahimi A, Pouraghaei M, Kafil B. Oleoylethanolamide, a bioactive lipid amide, as a promising treatment strategy for coronavirus/COVID-19. Arch Med Res. (2020) 51:464–7. 10.1016/j.arcmed.2020.04.006
- Moseley CE, Webster RG, Aldridge JR. Peroxisome proliferator-activated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice. Influenza Other Respir Viruses. (2010) 4:307–11. 10.1111/j.1750-2659.2010.00155.x
- Zimorovat A, Mohammadi M, Ramezani-Jolfaie N, Salehi-Abargouei A. The healthy Nordic diet for blood glucose control: a systematic review and meta-analysis of randomized controlled clinical trials. Acta Diabetol. (2020) 57:1–12. 10.1007/s00592-019-01369-8
- Ohe M, Shida H, Jodo S, Kusunoki Y, Seki M, Furuya K, et al. . Macrolide treatment for COVID-19: will this be the way forward? Biosci Trends. (2020) 14:159–60. 10.5582/bst.2020.03058
- Liu Q, Xiong H-r, Lu L, Liu Y-y, Luo F, Hou W, et al. . Antiviral and anti-inflammatory activity of arbidol hydrochloride in influenza A (H1N1) virus infection. Acta Pharmacol Sin. (2013) 34:1075–83. 10.1038/aps.2013.54
- Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. (2020) 14:58–60. 10.5582/ddt.2020.01012
- Humphreys IR, Walzl G, Edwards L, Rae A, Hill S, Hussell T. A critical role for OX40 in T cell-mediated immunopathology during lung viral infection. J Exp Med. (2003) 198:1237–42. 10.1084/jem.20030351
- Fu Y, Lin Q, Zhang Z, Zhang L. Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity. Acta Pharm Sin B. (2020) 10:414–33. 10.1016/j.apsb.2019.08.010
- Hernández A, Papadakos PJ, Torres A, González DA, Vives M, Ferrando C, et al. . Dos terapias conocidas podrían ser efectivas como adyuvantes en el paciente crítico infectado por COVID-19. Rev Española Anestesiol Reanimación. (2020) 67. 10.1016/j.redar.2020.03.004
- Kedzierski L, Linossi EM, Kolesnik TB, Day EB, Bird NL, Kile BT, et al. . Suppressor of cytokine signaling 4 (SOCS4) protects against severe cytokine storm and enhances viral clearance during influenza infection. PLoS Pathog. (2014) 10:e1004134. 10.1371/journal.ppat.1004134
- David S, Thamm K, Schmidt BMW, Falk CS, Kielstein JT. Effect of extracorporeal cytokine removal on vascular barrier function in a septic shock patient. J Intensive Care. (2017) 5:12. 10.1186/s40560-017-0208-1
- Ronco C, Reis T. Kidney involvement in COVID-19 and rationale for extracorporeal therapies. Nat Rev Nephrol. (2020) 16:308–10. 10.1038/s41581-020-0284-7
- Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. (2020) 55:105954. 10.1016/j.ijantimicag.2020.105954
- Zhang J, Huang J, Gu Y, Xue M, Qian F, Wang B, et al. . Inflammation-induced inhibition of chaperone-mediated autophagy maintains the immunosuppressive function of murine mesenchymal stromal cells. Cell Mol Immunol. (2020). 10.1038/s41423-019-0345-7
- Tobar N, Oliveira AG, Guadagnini D, Bagarolli RA, Rocha GZ, Araújo TG, et al. . Diacerhein improves glucose tolerance and insulin sensitivity in mice on a high-fat diet. Endocrinology. (2011) 152:4080–93. 10.1210/en.2011-0249
- Pavelka K, Bruyère O, Cooper C, Kanis JA, Leeb BF, Maheu E, et al. . Diacerein: benefits, risks and place in the management of osteoarthritis. an opinion-based report from the ESCEO. Drugs Aging. (2016) 33:75–85. 10.1007/s40266-016-0347-4
- Zhuo Y, Zhuo J. Tranilast Treatment Attenuates Cerebral Ischemia-Reperfusion Injury in Rats Through the Inhibition of Inflammatory Responses Mediated by NF-κB and PPARs. Clin Transl Sci. (2019) 12:196–202. 10.1111/cts.12606
- The Centre for Evidence-Based Medicine (CEBM) COVID-19 Registered Trials - and Analysis. Available online at: (accessed April 25, 2020).
- Ouellette DR, Moscoso EE, Corrales JP, Peters M. Sepsis outcomes in patients receiving statins prior to hospitalization for sepsis: comparison of in-hospital mortality rates between patients who received atorvastatin and those who received simvastatin. Ann Intensive Care. (2015) 5:9. 10.1186/s13613-015-0049-9
- US Food & Drug Administration (FDA) FDA Cautions Against Use of Hydroxychloroquine or Chloroquine for COVID-19 Outside of the Hospital Setting or a Clinical Trial Due to Risk of Heart Rhythm Problems. Available online at: (accessed June 18, 2020).
- Dutta A, Miaw SC, Yu JS, Chen TC, Lin CY, Lin YC, et al. . Altered T-bet dominance in IFN-γ-decoupled CD4+ T cells with attenuated cytokine storm and preserved memory in influenza. J Immunol. (2013) 190:4205–14. 10.4049/jimmunol.1202434
- Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. . Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. (2020) 117:10970–5. 10.1073/pnas.2005615117
- Lobentanzer S. Scavenging of interleukin 6 receptor by bioidentical recombinant Gp130 as intervention in Covid-19 exacerbation. OSF Preprints. 10.31219/
- Conti P, Ronconi G, Caraffa A, Gallenga C, Ross R, Frydas I, et al. . Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies. J Biol Regul Homeost Agents. (2020) 34:1. 10.23812/CONTI-E
- Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. . COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. (2020) 20:400–2. 10.1016/s1473-3099(20)30132-8
- Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact. J Infect. (2020). 10.1016/j.jinf.2020.04.017
- Chen R, Liang W, Jiang M, Guan W, Zhan C, Wang T, et al. . Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China. Chest. (2020) S0012-3692(20)30710-8. 10.1016/j.chest.2020.04.010
- Massachusetts General Hospital (MGH) Massachusetts General Hospital (MGH) COVID-19 Treatment Guidance. Available online at: (accessed April 26, 2020).
- Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. . Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. (2020) 382:e38. 10.1056/NEJMc2007575
- Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. . ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. (2020) 18:1023–6. 10.1111/jth.14810
- Internet Book of Critical Care (IBCC) Approach to Immunosuppression in Severe COVID-19. Available online at: (accessed April 25, 2020).
- Halyabar O, Chang MH, Schoettler ML, Schwartz MA, Baris EH, Benson LA, et al. . Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome. Pediatr Rheumatol Online J. (2019) 17:7. 10.1186/s12969-019-0309-6
- Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. . Surviving sepsis campaign: guidelines on the management of critically Ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med. (2020) 48:e440–69. 10.1097/ccm.0000000000004363
- Serrano-Castro PJ, Estivill-Torrús G, Cabezudo-García P, Reyes-Bueno JA, Ciano Petersen N, Aguilar-Castillo MJ, et al. . Impact of SARS-CoV-2 infection on neurodegenerative and neuropsychiatric diseases: a delayed pandemic? Neurología. (2020) 35:245–51. 10.1016/j.nrleng.2020.04.002
- Bao L, Deng W, Gao H, Xiao C, Liu J, Xue J, et al. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. bioRxiv. (2020) 2020.03.13.990226 10.1101/2020.03.13.990226
Source: PubMed